A recent study analyzed the minimal clinically important change (MCIC) in total motor Abnormal Involuntary Movement Scale (AIMS) score in patients with tardive dyskinesia (TD) treated with deutetrabenazine.

Read More > https://tardivedyskinesia.pocn.com/treatment/study-shows-deutetrabenazines-significant-impact-on-td-symptoms-reduction-in-motor-aims-score-linked-to-clinically-meaningful-improvement/